T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Clinical trials for T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to tame aggressive lymphoma
Disease control Recruiting nowThis early-stage study tests the safety of adding two targeted drugs (polatuzumab vedotin and possibly glofitamab) to standard chemotherapy for people with untreated, fast-growing B-cell lymphoma. About 56 participants will receive the combination to see if it is tolerable and ca…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 01, 2026 16:00 UTC
-
New combo therapy offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether adding the drug pembrolizumab to standard CAR-T cell therapy can improve outcomes for people with primary mediastinal B-cell lymphoma that has returned or not responded to prior treatment. About 35 adults will receive the combination and be followed for 6…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated May 01, 2026 15:58 UTC